Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating) [Seeking Alpha]
Scholar Rock Holding Corporation (SRRK)
Last scholar rock holding corporation earnings: 11/12 07:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The recent stock correction was due to manufacturing site issues, not clinical setbacks; approval is expected by 2026, presenting a speculative buy opportunity. Key risks include manufacturing delays and competition, but the pipeline and broad label potential make SRRK an attractive, de-risked neuromuscular play for risk-tolerant investors. I initiate Scholar Rock with a buy rating at $88 target price. Getty Images We Initiate Coverage On Scholar Rock With A Buy I initiate Scholar Rock with a speculative buy rating, as I believe Apitegromab is a de-risked asset, and the recent sell-off due to CRL is overdone. I plan to hold Scholar This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of SRRK either through stock ownership, options, or other derivatives. I wrote thi
Show less
Read more
Impact Snapshot
Event Time:
SRRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRRK alerts
High impacting Scholar Rock Holding Corporation news events
Weekly update
A roundup of the hottest topics
SRRK
News
- Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans [Yahoo! Finance]Yahoo! Finance
- Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Scholar Rock (NASDAQ:SRRK) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.MarketBeat
- Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $47.00. They now have an "overweight" rating on the stock.MarketBeat
- Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.MarketBeat
SRRK
Earnings
- 11/14/25 - Miss
SRRK
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 12/2/25 - Form 8-K
- SRRK's page on the SEC website